Q4 2025 · 13F-HR
Kalehua Capital Management LLCholdings as filed
Filed 2026-02-13 · accession 0002106181-26-000003
$101.1M
Reported value
19
Positions
2025-12-31
Period end
The Brief · Kalehua Capital Management LLC · Q4 2025
AI · grounded in 13F
Kalehua Capital Management LLC established a new position in Alpha Architect 1-3 Month Box Etf valued at $26.6M. The fund also initiated new stakes in X4 Pharmaceuticals Inc for $14.9M and SION for $8.1M. Additional new positions include RLAY at $7.6M and CMPS at $5.7M.
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 02072L565 | BOXX | Alpha Architect 1-3 Month Box Etf | $26.6M | 26.3% | 230,787 | Common | SOLE |
| 98420X202 | XFOR | X4 Pharmaceuticals Inc | $14.9M | 14.7% | 3,722,840 | Common | SOLE |
| 829401108 | SION | Sionna Therapeutics Inc | $8.1M | 8.02% | 197,072 | Common | SOLE |
| 75943R102 | RLAY | Relay Therapeutics Inc | $7.6M | 7.54% | 901,457 | Common | SOLE |
| 20451W101 | CMPS | Compass Pathways Plc | $5.7M | 5.59% | 819,692 | Common | SOLE |
| N69605108 | PHVS | Pharvaris NV | $5.5M | 5.46% | 198,772 | Common | SOLE |
| 81734D104 | SEPN | Septerna Inc | $5.4M | 5.36% | 194,544 | Common | SOLE |
| 687604108 | ORKA | Oruka Therapeutics Inc | $3.6M | 3.55% | 118,524 | Common | SOLE |
| 45719W205 | IKT | Inhibikase Therapeutics Inc | $3.6M | 3.55% | 1,750,000 | Common | SOLE |
| 019770106 | ALLO | Allogene Therapeutics Inc | $3.5M | 3.45% | 2,546,129 | Common | SOLE |
| 04746L203 | LONA | LeonaBio Inc | $3.0M | 2.95% | 393,701 | Common | SOLE |
| 61559X104 | MLTX | MoonLake Immunotherapeutics | $2.3M | 2.29% | 175,734 | Common | SOLE |
| 68622P109 | ORIC | Oric Pharmaceuticals Inc | $2.2M | 2.16% | 267,059 | Common | SOLE |
| 92511W207 | VRCA | Verrica Pharmaceuticals Inc | $2.0M | 1.94% | 235,779 | Common | SOLE |
| 90240B106 | TYRA | Tyra Biosciences Inc | $2.0M | 1.94% | 74,465 | Common | SOLE |
| 86889P208 | SRZN | Surrozen Inc | $1.9M | 1.87% | 385,178 | Common | SOLE |
| 87990A106 | TNYA | Tenaya Therapeutics Inc | $1.4M | 1.41% | 2,000,000 | Common | SOLE |
| 482929106 | KLRS | Kalaris Therapeutics Inc | $1.2M | 1.17% | 139,901 | Common | SOLE |
| 25253X207 | DMAC | Diamedica Therapeutics Inc | $759,058 | 0.75% | 95,359 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.